Immunotherapy for advanced renal cell cancer

Cytoreductive Nephrectomy Preceding Adjuvant Immunotherapy for Metastatic Renal Cell Carcinoma: 8 Years' Experience in a UK Tertiary Referral Centre

“…This is as a result of our oncologic protocol following surgery, where proven clinical or radiological progression were indications for systemic treatment initiation. As a result, the number of patients starting immunotherapy (14/40, 35%) is low but comparable to previous studies [6,7].…”

Cytoreductive Nephrectomy Preceding Adjuvant Immunotherapy for Metastatic Renal Cell Carcinoma: 8 Years' Experience in a UK Tertiary Referral Centre

“…This is as a result of our oncologic protocol following surgery, where proven clinical or radiological progression were indications for systemic treatment initiation. As a result, the number of patients starting immunotherapy (14/40, 35%) is low but comparable to previous studies [6,7].…”

Interferon Alpha and Metronomic Cyclophosphamide for Metastatic Kidney Cancer: A Phase 2 Study

“…CB was seen in 40% of treated patients. PFS and OS in the whole group on final analysis (4.6 and 13.2 months) were not satisfactory and comparable with data available in literature for IFN monotherapy (Coppin and others 2005). Additionally, we have observed only 2 PRs.…”

A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

“…The IFN regimen used in British Columbia was considered a standard regimen at the time and was virtually the same regimen used in the randomized phase 3 study. It is important to note that the overall survival observed in both our IFN and sunitinib groups was somewhat inferior to those in previously reported clinical trials, ranging from 13 to 14 months2‐5 and from 23.9 to 26.4 months,13, 24 respectively. The patients in the randomized trials are generally well selected, with good performance status compared with the patients in this study.…”

Cytoreductive Nephrectomy Preceding Adjuvant Immunotherapy for Metastatic Renal Cell Carcinoma: 8 Years' Experience in a UK Tertiary Referral Centre

“…This is as a result of our oncologic protocol following surgery, where proven clinical or radiological progression were indications for systemic treatment initiation. As a result, the number of patients starting immunotherapy (14/40, 35%) is low but comparable to previous studies [6,7].…”

Interferon Alpha and Metronomic Cyclophosphamide for Metastatic Kidney Cancer: A Phase 2 Study

“…CB was seen in 40% of treated patients. PFS and OS in the whole group on final analysis (4.6 and 13.2 months) were not satisfactory and comparable with data available in literature for IFN monotherapy (Coppin and others 2005). Additionally, we have observed only 2 PRs.…”

A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

“…The IFN regimen used in British Columbia was considered a standard regimen at the time and was virtually the same regimen used in the randomized phase 3 study. It is important to note that the overall survival observed in both our IFN and sunitinib groups was somewhat inferior to those in previously reported clinical trials, ranging from 13 to 14 months2‐5 and from 23.9 to 26.4 months,13, 24 respectively. The patients in the randomized trials are generally well selected, with good performance status compared with the patients in this study.…”

Cytoreductive Nephrectomy Preceding Adjuvant Immunotherapy for Metastatic Renal Cell Carcinoma: 8 Years' Experience in a UK Tertiary Referral Centre

“…This is as a result of our oncologic protocol following surgery, where proven clinical or radiological progression were indications for systemic treatment initiation. As a result, the number of patients starting immunotherapy (14/40, 35%) is low but comparable to previous studies [6,7].…”

Interferon Alpha and Metronomic Cyclophosphamide for Metastatic Kidney Cancer: A Phase 2 Study

“…CB was seen in 40% of treated patients. PFS and OS in the whole group on final analysis (4.6 and 13.2 months) were not satisfactory and comparable with data available in literature for IFN monotherapy (Coppin and others 2005). Additionally, we have observed only 2 PRs.…”

A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

“…The IFN regimen used in British Columbia was considered a standard regimen at the time and was virtually the same regimen used in the randomized phase 3 study. It is important to note that the overall survival observed in both our IFN and sunitinib groups was somewhat inferior to those in previously reported clinical trials, ranging from 13 to 14 months2‐5 and from 23.9 to 26.4 months,13, 24 respectively. The patients in the randomized trials are generally well selected, with good performance status compared with the patients in this study.…”